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ABSTRACT 27 
Background/Aims: Oral contraceptives (OC) and norethisterone acetate (NETA) are among first-28 
line medical therapies for symptomatic endometriosis, but their use is sometimes associated with 29 
intolerable side effects. We investigated whether shifting from low-dose OC to NETA (2.5 mg/day), 30 
or viceversa, improved tolerability.  31 
Methods 32 
Sixty-seven women willing to discontinue their treatment because of intolerable side effects despite 33 
good pain relief, were enrolled in a self-controlled study, and shifted from OC to NETA (n = 35) or 34 
from NETA to OC (n = 32). The main study outcome was satisfaction with treatment 12 months 35 
after the change. Tolerability, pain symptoms, health-related quality of life, psychological status, 36 
and sexual functioning were also evaluated. 37 
Results 38 
After treatment change, good tolerability was reported by 37% of participants who shifted to 39 
NETA, and by 52% of those who shifted to OC. At 12-month assessment, 51% of women intolerant 40 
to OC were satisfied with NETA, and 65% of those intolerant to NETA were satisfied with OC 41 
(intention-to-treat analysis). Other study variables did not vary substantially. 42 
Conclusions 43 
In selected endometriosis patients, shifting from OC to NETA, or viceversa, because of side effects, 44 
improved tolerability. Better results were observed when substituting NETA with OC rather than 45 
the other way round.46 
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INTRODUCTION 47 
Combined oral contraceptives (OC) and progestins are indicated by major international guidelines 48 
as the first-line medical treatment options for women not seeking conception and with 49 
endometriosis-associated pelvic pain [1-4]. Overall, about two thirds of patients appear to benefit 50 
from these therapies [5-16]. The main reason of treatment failure in the remaining third, in addition 51 
to inefficacy, is drug intolerance. As untoward effects of OCs and progestins partly differ, a shift 52 
from the former to the latter compounds, or viceversa, could allow continuing treatment with a safe, 53 
effective, and unexpensive medication without the need for stepping up to a drug with a less 54 
favorable therapeutic profile or resorting to surgery. However, very limited information is available 55 
on what should a patient expect from these changes [17, 18]. The answers to these questions seem 56 
important as the clinical issue is not rare and may interfere with health-related quality of life and 57 
disease management. Given this background, we sought to investigate whether shifting from an OC 58 
to a progestin, or viceversa, specifically because of drug intolerance, is of benefit in terms of relief 59 
from side effects and, in case these measures are effective, whether they imply reduced efficacy on 60 
pain symptoms.  61 
MATERIALS AND METHODS 62 
The main objective of the present study was to assess the proportion of patients satisfied with their 63 
therapy 12 months after a change from a low-dose, monophasic OC to norethisterone acetate 64 
(NETA), or viceversa, because of side effects intolerable to the point of requesting treatment 65 
discontinuation. Therefore, in the present study population, patient dissatisfaction was not caused 66 
by inefficacy on pain symptoms. Secondary objective was the evaluation of variations in pain 67 
symptoms, health-related quality of life, psychological status, and sexual function associated with 68 
the shift from OC to NETA, or viceversa. 69 
 A prospective, self-controlled study design was adopted because it allows within-person 70 
comparisons avoiding the potential confounding caused by differences between patients [19]. The 71 
investigation was performed in an academic department specializing in the management of 72 
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endometriosis, and the competent Institutional Review Board approved the study. Patients signed an 73 
informed consent form before enrollment. Women who denied their consensus were excluded. 74 
Patients 75 
 We considered 18- to 40-year old women, not seeking conception, with a surgical diagnosis 76 
of endometriosis in the previous 24 months or with a current non-surgical diagnosis of 77 
endometriosis, and using an OC or NETA for pelvic pain, but unwilling to continue the current 78 
treatment because of dissatisfaction due to intolerable side effects. Non-surgical diagnoses were 79 
based on previously published criteria [20-22]. Participants were recruited during the period August 80 
2014 - July 2015. 81 
 Women were informed that: i) OC or NETA may, in some women, cause side effects, 82 
frequently because of the estrogen component in the former case, and of residual androgenic 83 
activity in the latter case; ii) switching to, respectively, a progestin monotherapy or an OC 84 
containing another type of progestin could result in subjective improvement; iii) also the alternative 85 
drug was associated with side effects, and the efficacy of the proposed change of therapy was 86 
uncertain; iv) OCs and progestins are indicated by major international guidelines as the first-line 87 
treatment for endometriosis-associated pelvic pain [1-4], but that other medical therapies exist, 88 
although characterized by a less favorable balance between benefits, harms and costs [23-27]; v) 89 
laparoscopic surgery was a reasonable alternative in case they declined a change in pharmacological 90 
treatment, but that pain and lesion recurrence was about 10% a year without long-term 91 
postoperative medical therapy [28, 29].  92 
Treatments 93 
a. Switch from OC to NETA 94 
Norethisterone acetate, a 19-nortestosterone derivative progestin, has been repeatedly evaluated in 95 
women with endometriosis [6, 9-11, 30-32], and has been routinely used in our referral center for 96 
several years [7, 14-16]. Norethisterone acetate is approved by the FDA and the Italian Ministry of 97 
Health for the treatment of endometriosis and is reimbursed by the Italian National Health System. 98 
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Norethisterone acetate was prescribed at the dose of 2.5 mg once a day, per os. The progestin was 99 
started after 4-7 days since OC discontinuation, depending on the type of OC previously used.  100 
b. Switch from NETA to OC 101 
The OCs used in our center were monophasic formulations containing ethinyl-estradiol 0.015 mg 102 
and gestodene 60 mg or, in case of spotting, ethinyl-estradiol 0.02 mg and desogestrel 150 mg. In 103 
smokers and in those with a BMI ≥ 30, a combination of ethinyl-estradiol 0.02 mg and 104 
levonorgestrel 100 mg was prescribed. Women were allowed to choose between cyclic and 105 
continuous OC use based on their preference because the reason for the change of medication was 106 
intolerance, not inefficacy on pain. A pause without treatment was not suggested before starting 107 
OC.  108 
 NETA and OC were continued without preplanned time limits. However, for the purpose of 109 
the present study, only the first 12 months of use have been evaluated. In case of prolonged spotting 110 
(≥ 7 days) or breakthrough bleeding during NETA or continuous OC use, the patients were advised 111 
to discontinue treatment for one week in the former case, and 4-7 days in the latter case.  112 
Measurements 113 
 All patients assisted in our center systematically undergo clinical and ultrasonographic 114 
evaluation every six months. On these occasions, women are routinely asked to complete five 115 
questionnaires, two on pain (a numeric rating scale, NRS; and a multi-dimensional categorical 116 
rating scale, MCRS), one on quality of life (the Short Form-12 questionnaire, SF-12), one on 117 
psychological status (the Hospital Anxiety and Depression scale, HADS), and one on sexual 118 
functioning (the Female Sexual Function Index, FSFI). Women are also asked to indicate drug 119 
tolerability using a NRS and to rate the degree of satisfaction with their treatment. 120 
 The above scales and questionnaires have been described previously in detail [7, 13-16]. The 121 
presence and severity of dysmenorrhea, deep dyspareunia, non-menstrual pelvic pain, and dyschezia 122 
were assessed using an 11-point NRS, with 0 indicating absence of pain and 10 pain as bad as it 123 
could be. Patients were also asked to grade the severity of the above symptoms using a 0- to 3-point 124 
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MCRS modified from that devised by Biberoglu and Behrman [33]. Irregular bleeding during 125 
treatment was defined as spotting (scanty bleeding requiring ≤ 1 pad or tampon per day) or 126 
breakthrough bleeding (light or moderate bleeding requiring ≥ 2 pads or tampons per day). Pain 127 
during spotting or breakthrough bleeding was considered as dysmenorrhea.  128 
 The SF-12 health survey, developed from the original SF-36 questionnaire [34, 35], is a well 129 
know, validated self-administered 12-item instrument. It measures health dimensions covering 130 
functional status, well-being, and overall health. Information from the 12 items is used to construct 131 
physical (PCS-12) and mental (MCS-12) component summary measures [36, 37], with higher 132 
scores indicating better health perception. 133 
 The HADS questionnaire is a self-assessment mood scale specifically designed for use in 134 
non-psychiatric hospital outpatients to determine states of anxiety and depression. It comprises 14 135 
questions, 7 for the anxiety subscale and 7 for the depression subscale. Lower scores indicate better 136 
psychological status [38]. 137 
 The FSFI questionnaire is a 19-item, multidimensional, self-report instrument for evaluating 138 
the main categories of female sexual dysfunction and sexual satisfaction [39-41]. The transformed 139 
maximum score for each domain is 6, and the maximum (best) transformed full-scale score is 36, 140 
with a minimum full-scale score of 2.0.  141 
 Occurrence of side effects associated with medical treatments is actively investigated in our 142 
endometriosis outpatient clinic, and the overall tolerability of hormonal therapies is measured using 143 
a 0- to10-point NRS, with 0 indicating absolutely intolerable untoward effects and 10 absence of 144 
adverse effects. Scores are then categorized, with 9-10 indicating that a drug is very well tolerated; 145 
7-8, well tolerated; 5-6, moderately tolerated; 3-4, poorly tolerated; 0-2, not tolerated [16]. 146 
 Patients rated the degree of satisfaction after the modification of their treatment according to 147 
a five-category scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very 148 
dissatisfied) by answering the following question: “Taking into consideration the variations 149 
occurred in side effects and overall tolerability of treatment, pain symptoms, physical and 150 
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psychological well-being, health-related quality of life, and sexual functioning, how would you 151 
define the level of satisfaction with your current treatment?” In order to limit the potential effect of 152 
confounding, satisfaction with treatment, the main study outcome, was dichotomized into 153 
“satisfied” (very satisfied plus satisfied) and “dissatisfied” (neither satisfied nor dissatisfied plus 154 
dissatisfied plus very dissatisfied). 155 
Data management 156 
The focus of the investigation was not a head-to-head comparison between OC and NETA but, 157 
instead, quantification of the proportion of women who were satisfied with a change in treatment 12 158 
months after OC or NETA discontinuation because of intolerance. No study is available to define 159 
the potential benefits of shifting from OC to NETA or viceversa in this clinical condition. 160 
Therefore, a pre-planned power calculation was not performed, and we decided to include all the 161 
eligible patients evaluated in a 12-month period. 162 
 Data were archived using Excel 2003 (Microsoft Corporation, Redmond, Washington, 163 
U.S.A.) and exported in SPSS 18.0 (SPSS, Inc, Chicago, IL, U.S.A.) or SAS software 9.4 (SF-12 164 
data; SAS Institute Inc., Cary, NC, U.S.A.) for statistical analysis. Estimate of patient satisfaction 165 
rate was performed according to the intention-to-treat principle, considering as dissatisfied all 166 
patients who dropped out of the study for any reason except conception seeking, thus including 167 
request for surgery and lost to follow-up. Variations in drug tolerability, pelvic pain symptoms, 168 
health-related quality of life, psychological status, and sexual functioning between baseline and 12-169 
month values were evaluated by using the paired Student t test for normally distributed data, the 170 
non-parametric Wilcoxon matched pairs test for non-normally distributed data, the McNemar test 171 
for categorical variables, and the Fisher Exact test in case of cells without numerical data. 172 
Determinants of satisfaction with treatment were investigated with unpaired tests (Student t test for 173 
normally distributed continuous variables, Wilcoxon test for non-normally distributed continuous 174 
variables, and the chi-squared test for categorical variables). All statistical tests were two-sided. A P 175 
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value < 5% was considered statistically significant. When appropriate, 95% confidence intervals 176 
(CIs) were calculated for the observed differences by applying a binomial distribution model. 177 
RESULTS 178 
A total of 35 women shifted from OC to NETA, and 32 from NETA to OC. The distribution of 179 
demographic and clinical characteristics of the patients in the two study groups are shown in Table 180 
1. 181 
a. Switch from OC to NETA 182 
The median duration [interquartile range, IQR] of OC use was 6 months [3-14]. Nineteen women 183 
(54%) were using OC cyclically and 16 (46%) continuously. The most frequent untoward effects 184 
that determined the request for OC discontinuation despite an appreciable effect on pain symptoms 185 
were headache (49%), breakthrough bleeding (14%), and weight gain (11%). Eight women (23%) 186 
dropped out from the study between the 6- and 12-month evaluation owing to persistence of 187 
(headache, n = 3) or onset of different (mood changes, n = 1; urticarial rash, n = 1; breakthrough 188 
bleeding, n = 1) side effects, onset of non-menstrual pelvic pain (n = 1), and unwillingness to 189 
undertake any further treatment (n = 1). Variation of frequency of side effects associated with the 190 
shift from OC to NETA in the 27 women who completed the 12-month study period is reported in 191 
Table 2. None of the differences were statistically significant. A trend was observed toward a 192 
decrease in frequency of headache (from 56% to 30%) and an increase in that of weight gain (from 193 
30% to 44%). However, the severity of untoward effects decreased significantly, as the mean ± SD 194 
tolerability NRS score increased from 3.0 ± 1.6 to 5.7 ± 2.4 (P < 0.001). Ten women (37%) 195 
reported good or very good (NRS ≥ 7) drug tolerability, compared with none at baseline. 196 
 The severity of pain symptoms did not vary significantly except for dysmenorrhea that 197 
decreased at evaluation by means of the NRS (Table 3). Overall, the frequency of moderate or 198 
severe complaints was marginal at both baseline and 12-month assessment. No substantial 199 
variations were observed also in psychological status and sexual functioning. With regard to health-200 
related quality of life, a significant improvement was reported only in the physical component of the 201 
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SF-12 questionnaire (Table 3). At the end of the study period 18/35 (51%; 95% C.I., 36% to 67%) 202 
women were satisfied or very satisfied with the treatment change, whereas 17/35 (49%; 95% C.I., 203 
33% to 64%) were neither satisfied nor dissatisfied, dissatisfied, or very dissatisfied. All the patients 204 
who dropped out from the study were included as dissatisfied in this intention-to-treat analysis. 205 
 b. Switch from NETA to OC 206 
The median duration [interquartile range, IQR] of NETA use was 12 months [5-22]. The most 207 
frequent untoward effects that determined the request for NETA discontinuation despite an 208 
appreciable effect on pain symptoms were weight gain (19%), headache (16%), breakthrough 209 
bleeding (16%), decreased libido (16%), spotting (12%), and mood changes (12%). Seven women 210 
(22%) dropped out from the study between the 6- and 12-month evaluation owing to persistence of 211 
(acne, n = 1) or onset of different (headache, n = 4) side effects, onset of non-menstrual pelvic pain 212 
(n = 1), and pregnancy desire (n = 1). Variation of frequency of side effects associated with the shift 213 
from NETA to OC in the 25 women who completed the 12-month study period is reported in Table 214 
4. Again, none of the differences were statistically significant. A trend was observed toward a 215 
decrease in frequency of weight gain (from 36% to 16%), decreased libido (from 44% to 32%), and 216 
vaginal dryness (from 36% to 24%), and an increase in that of headache (from 20% to 40%). 217 
However, the severity of untoward effects decreased significantly, as the mean ± SD tolerability 218 
NRS score increased from 3.5 ± 1.7 to 6.9 ± 2.5 (P < 0.001). Thirteen women (52%) reported good 219 
or very good (NRS ≥ 7) drug tolerability, compared with none at baseline. 220 
 Based on NRS assessment, the severity of deep dyspareunia and non-menstrual pelvic pain 221 
decreased significantly (Table 5). A trend was observed toward a decrease in the frequency of 222 
moderate to severe deep dyspareunia (eight women at baseline vs three at 12 months) and dyschezia 223 
(four and two women, respectively) at MCRS evaluation (Table 5). Significant improvements were 224 
observed in both the anxiety and depression HADS subscales scores, as well as in the FSFI scores. 225 
No significant variations were reported in both the physical and the mental components of the SF-226 
12 questionnaire (Table 5). One woman who dropped out of the study because of pregnancy desire 227 
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was not considered in the intention-to-treat analysis of satisfaction with treatment. At the end of the 228 
study period 20/31 (65%; 95% C.I., 47% to 79%) patients were satisfied or very satisfied with the 229 
treatment change, whereas 11/31 (35%; 95% C.I., 20% to 52%) were neither satisfied nor 230 
dissatisfied, dissatisfied, or very dissatisfied.  231 
DISCUSSION 232 
Overall, the main finding of the present study was that, when OC or NETA are not tolerated, 233 
shifting to the other compound allows the majority of patients with endometriosis to improve 234 
tolerability and to continue medical treatment with a safe, effective, and unexpensive drug. The 235 
benefit seems larger when the shift is from NETA to OC rather than the other way round, as the 236 
proportion of satisfied patients at the end of the study period was, respectively, 65% and 51%. 237 
Moreover, in the latter case the 95% C.I.s of the rates of satisfied and dissatisfied women amply 238 
overlapped, whereas in the former case the 95% C.I. overlapping was marginal. 239 
 Considering a shift from OC to NETA may be beneficial especially in women experiencing 240 
headache, as previously suggested by Morotti et al. [17]. The frequency of the other untoward 241 
effects associated with OC use were not reduced, but their severity was, as demonstrated by the 242 
increase in 12-month follow-up NRS tolerability score compared with baseline values.  243 
 Considering a shift from NETA to OC may be beneficial especially in women experiencing 244 
side effects typically associated with this type of progestin, such as weight gain, acne, bloating, and 245 
decreased libido. On the other hand, this change may lead to an increase in the frequency of 246 
headache, likely associated with the estrogen component. This confirms that OCs with the lowest 247 
possible estrogen dose should be chosen also in women with endometriosis in order to improve both 248 
safety and tolerability [42-45].  249 
 The larger effect observed when the shift was from NETA to OC confirms that low-dose, 250 
monophasic estrogen-progestin combinations should retain their role in the management of 251 
endometriosis, provided pain symptoms are adequately relieved. In this regard, it should be 252 
highlighted that at baseline pain was generally well controlled in both study groups, and that the 253 
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focus here was on tolerability, not efficacy on symptoms. This also explains the limited significant 254 
variations in pain symptoms' severity independently of the direction of the change between the two 255 
medications, demonstrating that the observed amelioration of tolerability was not at detriment of 256 
efficacy on pain. Conversely, marginal improvements in the severity of dysmenorrhea when shifting 257 
from OC to NETA, and of deep dyspareunia and non-menstrual pain when shifting from NETA to 258 
OC were reported, although of questionable clinical importance. 259 
 Our study has limitations. The combination of the observational design with the limited 260 
sample size increases the risk of confounding. Moreover, the population was highly selected, and 261 
this precludes generalization of the results to endometriosis patients with different complaint types. 262 
However, the self-controlled design was chosen purposely because the objective of the study was to 263 
assess variations in tolerability when shifting to NETA or OC not in a general population using the 264 
other drug, but specifically in those patients who were dissatisfied because of intolerable side 265 
effects and that would have otherwise discontinued medical therapy. In a self-control study, 266 
recruited patients act as their own control, thus limiting the effect of confounding. In fact, study 267 
outcomes may be influenced by relevant characteristics that may differ between patients [19]. In 268 
addition, overoptimistic results should have been avoided, as patient satisfaction was assessed 269 
including all dropouts as dissatisfied. 270 
 The period of use of OC and NETA before changing medication was fairly long. Thus, the 271 
phenomenon of regression toward the mean seems unlikely, given that the clinical condition was 272 
chronic and that all study variables were measured repeatedly before enrollment. Also a carry-over 273 
effect should be ruled out, as the baseline patients' conditions were the worst possible in terms of 274 
tolerability. Therefore, if a carry-over effect was in play, this was detrimental, not beneficial, again 275 
potentially leading to conservative estimates. Also a placebo effect cannot be excluded. However, 276 
given the long study period, this seems little probable, as the placebo effect may not last for one 277 
year when drug tolerability is unacceptable. 278 
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 The proportion of dropouts was high and above the usually indicated 20% cut-off over 279 
which the study findings are considered of questionable validity [46]. However, this cut-off may not 280 
be appropriate when all patients at recruitment are considering abandonment of medical treatment 281 
owing to dissatisfaction. In these conditions, a 22-23% dropout rate may even appear fairly low. 282 
 Owing to the limited number of participants, the analysis of determinants of success was 283 
deemed unreasonable. More in general, the small sample size could have led to some type II errors, 284 
thus impeding the identification of potential factors predictive of satisfaction with treatment change. 285 
On the other hand, in our experience it is not easy for endometriosis patients to decide to 286 
discontinue a medical therapy that is effective on pain, solely because of side effects. In this regard, 287 
it may not be excluded that women referred or self-referred to our center are more motivated to 288 
choose medical rather that surgical treatment. If this was true, such selection bias would render 289 
generalization of the study results more problematic.  290 
 However, when discussing generalization, we also believe that our findings provide a 291 
realistic picture of what happens in everyday practice, and our data may help clinicians when 292 
counselling patients experiencing upsetting untoward effects with OC or NETA. Observational 293 
studies may be very helpful in assessing the real world effectiveness of treatments that have already 294 
been demonstrated to work in highly controlled research settings [47], as OCs and NETA in women 295 
with symptomatic endometriosis [5, 7, 8, 12]. 296 
 It could also be argued that, in women who were intolerant to NETA, instead of suggesting 297 
OC we could have suggested shifting to dienogest, that has been proven to be better tolerated than 298 
NETA [16]. However, many women assisted in our center cannot afford the cost of dienogest (€730 299 
- $860 - £ 670 per year in Italy, not reimbursed by the Italian NHS) and prefer NETA (€18 - $21 - 300 
£17 per year in Italy, €4 per year when reimbursed by the Italian NHS) specifically for economic 301 
reasons. Indeed, we previously demonstrated that the cost of dienogest limited its effectiveness 302 
despite its good tolerability [16]. Moreover, here the issue was not poor pain control, but drug 303 
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intolerance, and indeed the larger benefit was observed precisely when shifting from NETA to OC. 304 
Thus, changing for dienogest would have led to waste of money in the majority of patients. 305 
 In conclusion, when endometriosis-associated pain was relieved by OC or NETA, but the 306 
medications could no longer be used because of intolerable side effects, shifting to the other 307 
compound resulted in substantial improvement of tolerability in the majority of women. The change 308 
of therapy was particularly beneficial in patients using NETA who shifted to OC. Women should be 309 
informed about this further therapeutic option in order to be enabled to choose a treatment 310 
modification that is aligned with their preferences and priorities.  311 
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Table 1. Distribution of baseline demographic and clinical characteristics of women who shifted to norethisterone 
acetate (NETA) for intolerance to low-dose oral contraceptive (OC), and of women who shifted to OC for 
intolerance to NETA.  
    
Characteristic 
From OC to NETA 
study group 
(n = 35) 
From NETA to OC 
study group 
(n = 32) 
   
Age (years) 35.5 ± 4.7 34.2 ±  
BMI (Kg/m2) 23.6 ± 4.0 20.5 ± 2.6 
Smoking 6 (17%) 9 (28%) 
Previous deliveries 15 (43%) 6 (19%) 
Previous surgical procedures for endometriosis   
None 9 (26%) 14 (44%) 
1 18 (51%) 11 (34%) 
2 7 (20%) 5 (16%) 
≥ 3 1 (3%) 2 (6%) 
Endometriotic lesion typea   
Deep infiltrating endometriosis 17 (49%) 24 (75%) 
Ovarian endometriomas 28 (80%) 18 (56%) 
Pain symptomsb   
Dysmenorrhea 15 (42%) 8 (25%) 
Deep dyspareunia 5 (15%)c 15 (30%)d 
Non-menstrual pelvic pain 5 (14%) 12 (37%) 
Dyschezia 2 (6%) 7 (22%) 
   
Duration of previous treatment [months] 6 [3-14] 12 [5-22] 
      
   
Data is reported as mean ± SD, or number (percentage), or median [interquartile range]. 
NETA = norethisterone acetate. OC = low-dose, combined oral contraceptive. BMI = body mass index. 
a The sum does not add to the total as some women had both lesion types. 
bNumeric rating scale > 0. Mild pain symptoms are also included. 446 
cOne woman did not have sexual intercourses at basal and/or at 12-month evaluation.  447 
dTwo women did not have sexual intercourses at basal and/or at 12-month evaluation 448 
449 
Vercellini et al., 21 
 450 
Table 2. Per-protocol analysis of frequency of side effects reported at baseline and at 
12-month evaluation by patients (n = 27) shifting from OC to NETA.  
    
Side effecta 
 Baseline 
evaluation 
12-month 
evaluation 
P 
    
    
  Headache 15 (56%) 8 (30%) NS 
  Spotting 5 (18%) 6 (22%) NS 
  Breakthrough bleeding 1 (4%) 0 (0%) NS 
  Weight gain 8 (30%) 12 (44%) NS 
  Nausea 2 (7%) 1 (4%) NS 
  Decreased libido 7 (26%) 5 (18%) NS 
  Vaginal Dryness 4 (15%) 6 (22%) NS 
  Bloating or swelling 5 (18%) 6 (22%) NS 
  Breast tenderness 0 (0%) 4 (15%) NS 
  Acne 0 (0%) 3 (11%) NS 
  Alopecia 0 (0%) 0 (0%) NS 
  Mood changes 5 (18%) 5 (18%) NS 
  Others 11 (41%) 9 (33%) NS 
        
aSome women reported more than one side effect. 
Data are number (percentage). 
  
   
 
 451 
452 
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Table 3. Per-protocol analysisa of pain symptoms, health-related quality of life, 
psychological status, and sexual functioning scores variation between baseline and 12-
month evaluation in patients (n = 27) shifting from OC to NETA. 
    
Symptoms / Questionnaires 
 Baseline 
evaluation 
12-month 
evaluation 
P 
    
Dysmenorrhea    
NRS 0 [0-4] 0 [0-0] 0.01 
MCRS ≥ 2 2 (7%) 0 (0%) NS 
    
Deep dyspareuniab    
NRS 0 [0-0] 0 [0-0] NS 
MCRS ≥ 2 1 (4%) 2 (8%) NS 
    
Non-menstrual pelvic pain    
NRS                                              0 [0-0] 0 [0-0] NS 
MCRS ≥ 2 1 (4%) 0 (0%) NS 
    
Dyschezia    
NRS 0 [0-0] 0 [0-0] NS 
MCRS ≥ 2 1 (4%) 0 (0%) NS 
    
SF-12    
Physical component 50.0 ± 11.1 55.4 ± 4.5 0.03 
Mental component  40.0 ± 11.7 42.6 ±13.2 NS 
 
HADS     
Anxiety 6.6 ± 4.3 5.9 ± 4.6 NS 
Depression 5.8 ± 4.3 5.4 ± 5.1 NS 
Total 12.4 ± 8.1 11.3 ± 9.1 NS 
    
FSFI total scoreb 26.2 ± 5.7 26.2 ± 6.7 NS 
        
Data is reported as mean ± SD, or number (percentage), or median [interquartile range]. 
NRS = 0 to 10-point numeric rating scale. MCRS = 0 to 3-point multidimensional 
categorical rating scale modified from that devised by Biberoglu and Behrman [33]. 
SF-12 = Short Form-12 [36, 37]. HADS = Hospital Anxiety and Depression Scale [38]. 
FSFI = Female Sexual Function Index [39, 40].  
NS = not significant. 
aWomen who withdrew before 12-month follow-up assessment (n = 8) were excluded. 
bOne woman did not have sexual intercourses either at baseline and/or at 12-month evaluation. 
Vercellini et al., 23 
 455 
Table 4. Per-protocol analysis of frequency of side effects reported at baseline and at 
12-month evaluation by patients (n = 25) shifting from NETA to OC. 
    
Side effecta 
Baseline 
evaluation 
12-month 
evaluation 
P 
    
  Headache 5 (20%) 10 (40%) NS 
  Spotting 4 (16%) 7 (28%) NS 
  Breakthrough bleeding 3 (12%) 0 (0%) NS 
  Weight gain 9 (36%) 4 (16%) NS 
  Nausea 2 (8%) 0 (0%) NS 
  Decreased libido 11 (44%) 8 (32%) NS 
  Vaginal Dryness 9 (36%) 6 (24%) NS 
  Bloating or swelling 4 (16%) 2 (8%) NS 
  Breast tenderness 0 (0%) 0 (0%) NS 
  Acne 2 (8%) 0 (0%) NS 
  Alopecia 0 (0%) 0 (0%) NS 
  Mood changes 5 (20%) 1 (4%) NS 
  Others 5 (20%) 1 (4%) NS 
        
aSome women reported more than one side effect. 
Data are number (percentage). 
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Table 5. Per-protocol analysisa of pain symptoms, health-related quality of life, 
psychological status, and sexual functioning scores variation between baseline 
and 12-month evaluation in patients (n = 25) shifting from NETA to OC. 
    
Symptoms / Questionnaires 
Baseline 
evaluation 
12-month 
evaluation 
P 
    
Dysmenorrhea    
NRS                                                 0 [0-1.5] 0 [0-3] NS 
MCRS ≥ 2 0 (0%) 1 (4%) NS 
    
Deep dyspareuniab    
NRS 5 [0-8] 0 [0-5.5] 0.02 
MCRS ≥ 2 8 (35%) 3 (13%) NS 
    
Non-menstrual pelvic pain    
NRS 
 
0 [0-4.5] 0 [0-0] 0.02 
MCRS ≥ 2 2 (8%) 1 (4%) NS 
    
Dyschezia    
NRS 
     
0 [0-1.5] 0 [0-0] NS 
MCRS ≥ 2 4 (16%) 2 (8%) NS 
    
HADS     
Anxiety 4.7 ± 3.5 3.6 ± 3.2 0.02 
Depression 5.4 ± 4.0 3.8 ± 3.4 0.03 
Total 10.1 ± 7.3 7.4 ± 6.3 0.02 
    
SF-12    
Physical component 52.8 ± 9.1 54.8 ± 4.4 NS 
Mental component 42.1 ± 11.7 46.1 ± 10.0 NS 
    
FSFI total scoreb 21.9 ± 8.6 25.4 ± 7.9 0.01 
        
Data is reported as mean ± SD, or number (percentage), or median [interquartile range]. 
NRS = 0 to 10-point numeric rating scale. MCRS = 0 to 3-point multidimensional categorical 
rating scale modified from that devised by Biberoglu and Behrman [33]. 
SF-12 = Short Form-12 [36, 37]. HADS = Hospital Anxiety and Depression Scale [38].  
FSFI = Female Sexual Function Index [39, 40].  
NS = not significant. 
aWomen who withdrew before 12-month follow-up assessment (n = 7) were excluded. 
bOne woman did not have sexual intercourses either at baseline and/or at 12-month evaluation. 
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